Aphios® Pharma is developing FDA-approved, cannabis-based drugs for treating highly unmet central and peripheral nervous system disorders of opioid addiction, pain, anxiety, epilepsy and Multiple Sclerosis that are only partially and anecdotally addressed by medical marijuana.

Aphios® Pharma is dedicated to the delivery, development and commercialization of cannabis-based drugs for CNS and other debilitating disorders. We will manufacture and utilize pharmaceutical-grade pure natural cannabinoids in stable, bioavailable nanoformulations, following cGMP guidelines of the FDA and Schedule 1 requirements of the Drug Enforcement Administration (DEA). These cannabinoid nanoformulations will be used to establish clinical evidence for treating highly unmet central and peripheral nervous system disorders such as chronic pain, cancer induced peripheral neuropathic pain, opioid and substance use disorders, anxiety, epilepsy and Multiple Sclerosis that are only partially and anecdotally addressed by medical marijuana.

Apart from the recent FDA approval of Epidiolex (GW Pharma, London, England) for specific cases of childhood epilepsy, there is little rigorous clinical evidence of the efficacy of cannabinoids for significant peripheral and central nervous system neurological disorders, and lack of availability of pharmaceutical-grade cannabinoids to conduct rigorous clinical studies. These issues are compounded by a prohibitive DEA, NIH and FDA regulatory environment for developing FDA-approved, cannabis-based drugs. From a technical perspective, cannabinoids are very hydrophobic (poorly water soluble) making formulation difficult and bioavailability poor; also, cannabinoids are very oxygen sensitive and unstable, contributing to inconsistencies in therapeutic performance. After FDA approval of Epidiolex, Jazz Pharmaceuticals acquired GW Pharma for $7.2 billion.

We plan to initially develop, in compliance with the DEA, FDA-approved cannabinoid nanotherapeutics that target CIPNP and opioid use disorder. Later, we plan to develop cannabinoid nanotherapeutics that target anxiety, epilepsy and Multiple Sclerosis.

469 Mystic Street
87 Main Street
North Reading, MA 01864
United States
Map It